Combining Immunotherapy With Anti-Rejection Drugs Can Treat ...| MENAFN.COM

Sunday, 14 August 2022 02:56 GMT

Combining Immunotherapy With Anti-Rejection Drugs Can Treat Cancer, Prevent Kidney Transplant Rejection


(MENAFN- Investor Brand Network)

Most kidney transplant patients usually stop taking their immunosuppressive drugs before starting cancer immunotherapy treatment to diminish the chances of their immune systems attacking the transplanted organs. However, a new study has found that combining standard antirejection medication and immune checkpoint inhibitors may benefit kidney transplant patients who suffer from terminal cancer.

Immune checkpoint inhibitors are drugs designed to block checkpoints, which are proteins that prevent immune responses in the body from being too…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Aditxt Inc. (NASDAQ: ADTX) are available in the company's newsroom at 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime . As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text“Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit 

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: 

BioMedWire (BMW)
San Francisco, California

415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork .

MENAFN05082022000224011066ID1104653333


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.